JERSEY CITY, N.J., Oct. 24, 2011 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) today announced that it has appointed Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to its Scientific Advisory Board. Dr. Segraves and Dr. Pyke will help guide the clinical development of S1's lead product, Lorexys, as it prepares for Phase I clinical trials.
"We are pleased to be able to attract such knowledgeable and prominent individuals as Segraves and Pyke to participate as members of our Scientific Advisory Board," stated Nicolas G. Sitchon, MA, MBA, Chief Executive Officer of S1 Pharmaceuticals. "The formation of a distinguished advisory board to provide medical, clinical, and strategic guidance to the Company marks the next step in the evolution of our Lorexys clinical development program."
Dr. Segraves is a professor of psychiatry at Case Western Reserve School of Medicine. Among his scientific interests are the treatment of sexual disorders, the co-morbidity of sexual dysfunction with anxiety and depressive disorders, sexual side effects of pharmacological agents, and pharmacotherapy of sexual disorders. Dr. Segraves has authored over 200 publications in the area of human sexuality, numerous international presentations, and five texts. He sits on the editorial board of the International Journal of Impotence Research and is the current editor of the Journal of Sex and Marital Therapy. Dr. Segraves obtained his M.D. from Vanderbilt University, his PhD from the University of London, and completed his residency in psychiatry at the University of Chicago.
Dr. Pyke served as Director of Clinical Research at Boehringer Ingelheim Pharmaceuticals where he led the Flibanserin Worldwide premenopausal HSDD clinical program that ended in October 2010. Dr. Pyke has a distinguished career of leading drug after drug to FDA approval with Parke-Davis, Bristol-Myers Squibb, and Upjohn. He has continued his clinical practice treating anxiety, depression, and substance abuse. Dr. Pyke is a member of numerous societies, including the International Society for the Study of Women's Sexual Health. He completed his Ph.D. at the University of Wisconsin, Madison, obtained his M.D. at the University of Miami, and completed his medical training in Internal Medicine at the University of Michigan.
"I look forward to serving on the advisory board for this promising potential therapy," stated Pyke. "The field of sexual health is ever evolving and it's exciting to join a company that is on the leading edge of this evolution."
About S1 Pharmaceuticals, Inc.
S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health. The most common type of Female Sexual Dysfunction (FSD) is a loss of libido and lack of sexual interest known as Hypoactive Sexual Desire Disorder (HSDD). S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.
|SOURCE S1 Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved